pancreastatin

A 49 residue post-translational fragment of chromogranin A that inhibits insulin secretion; amino acid sequence given in first source; the 49-amino acid peptide is from pig; human pancreastatin has 52 amino acids (hCgA 250-310) ; see also record for human pancreastatin

Also Known As:

Networked: 111 relevant articles (3 outcomes, 13 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Gayen, Jiaur R: 11 articles (01/2022 - 10/2009)
2.	Syed, Anees A: 7 articles (11/2021 - 01/2018)
3.	Mahata, Sushil K: 7 articles (11/2019 - 10/2002)
4.	Gupta, Anand P: 6 articles (01/2022 - 01/2018)
5.	O'Connor, Daniel T: 6 articles (01/2015 - 10/2002)
6.	Singh, Pragati: 5 articles (11/2021 - 08/2019)
7.	Riyazuddin, Mohammed: 5 articles (08/2020 - 01/2018)
8.	Valicherla, Guru R: 5 articles (08/2020 - 01/2018)
9.	Garg, Richa: 4 articles (01/2022 - 08/2019)
10.	Husain, Athar: 4 articles (11/2021 - 10/2019)

Related Diseases

1.	Insulin Resistance 11/01/2023 - "Pancreastatin inhibitor PSTi8 ameliorates insulin resistance by decreasing fat accumulation and oxidative stress in high-fat diet-fed mice." 10/01/2019 - "Pancreastatin inhibitor, PSTi8 ameliorates metabolic health by modulating AKT/GSK-3β and PKCλ/ζ/SREBP1c pathways in high fat diet induced insulin resistance in peri-/post-menopausal rats." 01/15/2022 - "Therefore, in the present work, we sought to test Pancreastatin inhibitor PSTi8 to ameliorate FFA-induced hepatic insulin resistance in in vitro and in vivo models. " 02/04/2010 - "Exogenous pancreastatin treatment restored insulin sensitivity in the Chga KO to near-normal levels. " 05/26/1994 - "These results suggest a role of pancreastatin in the possible mechanisms involved in insulin resistance."
2.	Fatty Liver 11/01/2023 - "Immunometabolic impact of pancreastatin inhibitor PSTi8 in MCD induced mouse model of oxidative stress and steatohepatitis." 08/01/2019 - "Pancreastatin inhibitor activates AMPK pathway via GRP78 and ameliorates dexamethasone induced fatty liver disease in C57BL/6 mice." 08/01/2019 - "To investigate the role of pancreastatin inhibitor (PSTi8) in lipid homeostasis and insulin sensitivity in dexamethasone induced fatty liver disease associated type 2 diabetes. "
3.	Neoplasms (Cancer) 11/01/1991 - "Immunohistochemical study of the distribution of pancreastatin in endocrine tumors of the pancreas and in normal pancreatic tissue: analysis of autopsy cases." 07/01/2010 - "This highly specific, sensitive pancreastatin assay can detect small changes in liver tumor progression and is up to 100-fold more sensitive and specific than CgA assays in the United States." 03/01/2007 - "Although safe, it should be approached cautiously in patients with significant tumor burden as evidenced by pancreastatin levels > or =5,000 pg/ml. We do not recommend whole-liver embolization in these patients but prefer a staged approach to each lobe of the liver." 11/01/1991 - "Using sixteen cases (sixteen lesions) of endocrine tumor of the pancreas, found in 1,300 consecutive autopsy cases (661 men and 639 women; mean age, 79.0 years), we examined distribution patterns of pancreastatin (PST) in these endocrine tumors and in normal tissues around them, using immunohistochemical staining. " 04/30/1990 - "It has been characterized that cell line QGP-1 derived from human non-functioning pancreatic islet cell tumor produces human pancreastatin. "
4.	Diabetes Mellitus 01/01/2018 - "Discovery of pancreastatin inhibitor PSTi8 for the treatment of insulin resistance and diabetes: studies in rodent models of diabetes mellitus." 10/01/2012 - "Study of the involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas." 10/01/2012 - "These results argue against a role of pancreastatin in the pathogenesis of diabetes mellitus associated with nonsecreting pituitary adenomas." 10/01/2012 - "An immunostaining against pancreastatin was found in a majority of pituitary adenomas, associated or not with diabetes mellitus. " 10/01/2012 - "We evaluated the possible involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas. "
5.	Pituitary Neoplasms (Pituitary Adenoma) 10/01/2012 - "Immunohistochemistry against pancreastatin was performed in 5 patients of each of the 3 groups of pituitary adenomas. " 10/01/2012 - "Study of the involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas." 10/01/2012 - "These results argue against a role of pancreastatin in the pathogenesis of diabetes mellitus associated with nonsecreting pituitary adenomas." 10/01/2012 - "An immunostaining against pancreastatin was found in a majority of pituitary adenomas, associated or not with diabetes mellitus. " 10/01/2012 - "We evaluated the possible involvement of pancreastatin in the physiopathology of diabetes mellitus associated with nonsecreting pituitary adenomas. "

Related Drugs and Biologics

1.	Dexamethasone (Maxidex)
2.	Endoplasmic Reticulum Chaperone BiP
3.	Chromogranin A
4.	Peptides (Polypeptides)
5.	Insulin (Novolin)
6.	Biomarkers (Surrogate Marker)
7.	Amino Acids
8.	Tumor Biomarkers (Tumor Markers)
9.	Prolactin
10.	Somatostatin (Somatotropin Release-Inhibiting Factor)

Related Therapies and Procedures

1.	Therapeutics
2.	Heterologous Transplantation (Xenotransplantation)